McBride PLC Announces EUR 40 Million Eurotab Acquisition and Trading Conditions Update

McBride's €40m Eurotab buy strengthens its tablet lead, lifts margins & is EPS-accretive. Deal funded from facilities amid input cost inflation.

2 April 2026by Joshua Thompson5 min read139 views

This article covers information on McBride PLC.

LON:MCB

McBride to buy Eurotab for EUR 40 million: the tablet specialist that slots neatly into Unit Dosing

McBride has tabled a binding offer to acquire Eurotab Group for an expected EUR 40 million (£34.5 million) in cash, with customary closing adjustments. Eurotab designs and manufactures solid-format cleaning and hygiene products – think dishwasher tablets, moisture absorbers and disinfecting bleach tablets – serving private label and contract manufacturing customers across Europe.

This deal is squarely in McBride’s sweet spot. It deepens the Unit Dosing division’s leadership in tablet-format detergents, adds two new product categories, relieves capacity constraints and broadens the customer offering. On the numbers, it’s pitched as immediately earnings-accretive from completion in the CEO’s words, and accretive in the first full year in the main text, with a clear path to higher Group margins.

What McBride is buying: Eurotab in brief

Eurotab is a privately owned specialist in precision powder compaction – the tech behind consistent, high-performing cleaning tablets. The business has two specialised plants in France and a smaller facility near Istanbul, serving Turkey. For the year to 30 June 2026, Eurotab is expected to post consolidated revenues of EUR 65 million, mostly in Europe.

Strategically, this plugs straight into McBride’s plan: more scale in tablets, more capacity headroom without heavy capex, and a foothold in Turkey to access new markets over time. It should also deepen relationships with key European retailers, which is handy when you’re selling private label at scale.

Deal terms, valuation and financing

Buyer	McBride Unit Dosing division
Target	Eurotab Group
Expected consideration	EUR 40 million (£34.5 million) cash, subject to closing adjustments
Enterprise value (anticipated)	EUR 38.2 million plus EUR 1.8 million for acquired tax losses
Revenue (Eurotab, expected)	EUR 65 million (year to 30 June 2026)
EBITDA multiple	5.2x underlying; 4.6x net of acquired tax losses; 3.1x when adjusting for conservative synergies
Funding	Existing banking facilities
Share buyback	Unaffected

Quick jargon buster: enterprise value (EV) is the total value of the business including debt and cash; EBITDA is a profit measure before interest, tax, depreciation and amortisation; and “synergies” are the cost or revenue benefits from combining two businesses. McBride also expects to utilise acquired tax losses over time, which improves the effective valuation.

Earnings uplift and margin progress

Management says the acquisition will be accretive to earnings per share (EPS) in the first full year of ownership; the CEO goes further, saying it should be immediately accretive from completion. Either way, the direction of travel is positive.

Share𝕏 in

Investing
Polar Capital Technology Trust Reports 102% NAV Growth in Stellar Fiscal Year
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Investing

Tagged

Last updated

5 July 2026

Star Rating

No ratings yet

Importantly, Eurotab’s contribution is expected to lift the Group’s EBITDA margin by approximately 0.5 percentage points, nudging McBride towards its 10% target set at the 2024 Capital Markets Day. That’s notable because margin expansion is a core plank of the equity story.

EBITDA margin is simply EBITDA divided by revenue – a good indicator of operating efficiency before non-cash and financing items.

Funding, leverage and balance sheet discipline

The deal will be funded from existing banking facilities. Net debt to EBITDA is expected to be slightly above the 1.5x target for approximately one year post completion. For context, net debt/EBITDA measures leverage; sitting just over 1.5x for a short period is modest for a business of McBride’s scale and should be manageable if trading remains sound.

Approvals and timing to close

There are some hurdles to clear. Under French law, acceptance of McBride’s offer is subject to information and consultation procedures with Eurotab’s French employees and representative bodies. Final sale and purchase documentation is expected to be signed once those procedures complete, and the transaction will be subject to certain other conditions to completion.

If all goes to plan, completion is anticipated between June 2026 and the end of the first quarter of McBride’s 2027 financial year.

Trading conditions: passing through input cost inflation

Alongside the deal, McBride flagged shifting trading conditions linked to the conflict in the Middle East. Initially, the impact was mostly higher haulage costs from fuel prices. Now, the squeeze is broadening: chemical and packaging suppliers are hiking prices to recover higher petrochemical feedstocks and energy costs. Early signs of possible supply shortages are emerging.

McBride expects elevated input costs in April and further increases in the near term. The company has already notified all customers of temporary price adjustments or surcharges to recover these beyond-our-control costs. Historically, private label cleaning products have shown resilient and growing demand in periods of macro uncertainty, which should help support volumes even as pricing flexes.

Why this matters for shareholders

This looks like a well-judged bolt-on. The price implies a 5.2x EBITDA multiple, dropping to 4.6x when netting off acquired tax losses and 3.1x after conservative synergies – attractive for a specialist asset that strengthens McBride’s leadership in European tablets and eases capacity bottlenecks. Add the 0.5 percentage point margin uplift and EPS accretion, and the financial logic is compelling.

The Turkish foothold is a quiet positive: it offers a platform into adjacent markets with optionality over time, without heavy upfront capital spend. Keeping the buyback running while executing the deal underlines the Board’s view that the shares remain undervalued.

Risks are sensible and knowable. There’s execution risk in integrating Eurotab and delivering synergies, potential timing slippage due to French employee consultation, and some near-term noise from input cost inflation and supplier price rises. Passing through temporary surcharges should defend margins, but there’s always a risk of pushback or short-term volume friction.

Bull points

Strategic fit in Unit Dosing with new product categories and deeper retail relationships.
Attractive valuation multiples with clear synergy potential.
EPS accretion and a circa 0.5 percentage point uplift to Group EBITDA margin, supporting the 10% target.
Capacity relief without major capex; improved security of supply and service levels.
Financed from existing facilities; buyback continues, signalling confidence.

Watch-outs

Completion conditional on French employee consultations and other approvals; timing not guaranteed.
Input cost inflation and emerging supply tightness could pressure near-term margins until surcharges flow through.
Integration and synergy delivery risk as with any acquisition.
Leverage nudges above the 1.5x target for about a year post completion.

Key figures at a glance

Expected cash consideration	EUR 40 million (£34.5 million)
Anticipated enterprise value	EUR 38.2 million plus EUR 1.8 million for acquired tax losses
Eurotab revenue (expected, FY to 30 June 2026)	EUR 65 million
EBITDA multiple	5.2x (4.6x net of tax losses; 3.1x with conservative synergies)
EBITDA margin impact	Approximately +0.5 percentage points to Group margin
Leverage (post completion)	Net debt/EBITDA slightly above 1.5x for approximately one year
Closing window (anticipated)	Between June 2026 and end of Q1 FY2027
Share buyback	No impact

Bottom line

This is a tidy, strategically aligned acquisition on sensible terms that should lift earnings and margins while strengthening McBride’s European tablet franchise. Short-term cost inflation is a headwind, but McBride is moving to pass through increases, and private label demand has historically held up in choppier markets. If executed cleanly, Eurotab should help McBride edge closer to that 10% EBITDA margin target and reinforce the case that the shares are undervalued.